Composites with Ivacaftor and Colistin for Cystic Fibrosis and Bacterial Lung Infection Treatment

Back to all technologies
Download as PDF
2020-ZHOU-68954
Intravenous and oral antibiotics are not always effective for lung infections due to limited drug exposure at the infection site and bacterial resistance.

Researchers at Purdue University have developed a novel combination therapy of polymyxins for treating bacterial lung infections. Polymyxins have often been used as the last-line resort for infections caused by multi-drug resistant Gram-negative ‘superbugs’; but Inhaled polymyxins can cause toxicity in the lungs. The novel formulation developed by Purdue researchers creates a powerful therapeutic option with better antibacterial killing and much-reduced toxicity than the polymyxins alone. The Purdue dry powder formulation shows promise as an inhaled therapy, with satisfactory stability and high aerosolization performance. This innovative inhalation formulation promises a life-saving option for patients suffering from bacterial lung infections, including people infected by multidrug-resistant Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacterales.


Advantages:
-Enhanced efficacy
-Decreased drug resistance
-Decreased toxicity

Potential Applications:
-Pharmaceuticals
-Biomedical
-Medicine

Related Publication:
Inhalable Nanocomposite Microparticles with Enhanced Dissolution and Superior Aerosol Performance
Mol. Pharmaceutics, Published online July 24, 2020
https://doi.org/10.1021/acs.molpharmaceut.0c00390
Mar 5, 2021
PCT-Patent
WO
(None)
(None)

Mar 11, 2020
Provisional-Gov. Funding
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org